- Home
- ILPT vs VOR Comparison
ILPT vs VOR Comparison
Compare ILPT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- VOR
- Stock Information
- Founded
- ILPT 2017
- VOR 2015
- Country
- ILPT United States
- VOR United States
- Employees
- ILPT N/A
- VOR N/A
- Industry
- ILPT Real Estate Investment Trusts
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- VOR Health Care
- Exchange
- ILPT Nasdaq
- VOR Nasdaq
- Market Cap
- ILPT 217.6M
- VOR 202.4M
- IPO Year
- ILPT 2018
- VOR 2021
- Fundamental
- Price
- ILPT $5.99
- VOR $2.30
- Analyst Decision
- ILPT Buy
- VOR Buy
- Analyst Count
- ILPT 2
- VOR 7
- Target Price
- ILPT $10.00
- VOR $3.77
- AVG Volume (30 Days)
- ILPT 745.4K
- VOR 47.3M
- Earning Date
- ILPT 07-29-2025
- VOR 08-07-2025
- Dividend Yield
- ILPT 0.67%
- VOR N/A
- EPS Growth
- ILPT N/A
- VOR N/A
- EPS
- ILPT N/A
- VOR N/A
- Revenue
- ILPT $441,992,000.00
- VOR N/A
- Revenue This Year
- ILPT $3.09
- VOR N/A
- Revenue Next Year
- ILPT $1.79
- VOR N/A
- P/E Ratio
- ILPT N/A
- VOR N/A
- Revenue Growth
- ILPT 0.61
- VOR N/A
- 52 Week Low
- ILPT $2.45
- VOR $0.13
- 52 Week High
- ILPT $6.00
- VOR $3.29
- Technical
- Relative Strength Index (RSI)
- ILPT 84.50
- VOR 78.77
- Support Level
- ILPT $4.50
- VOR $2.25
- Resistance Level
- ILPT $4.77
- VOR $3.29
- Average True Range (ATR)
- ILPT 0.23
- VOR 0.52
- MACD
- ILPT 0.09
- VOR 0.18
- Stochastic Oscillator
- ILPT 98.73
- VOR 82.52
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.